BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

670 related articles for article (PubMed ID: 27759437)

  • 1. The achievement of ligand-functionalized organic/polymeric nanoparticles for treating multidrug resistant cancer.
    Lee WH; Loo CY; Leong CR; Young PM; Traini D; Rohanizadeh R
    Expert Opin Drug Deliv; 2017 Aug; 14(8):937-957. PubMed ID: 27759437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoparticle approaches to combating drug resistance.
    Moon JH; Moxley JW; Zhang P; Cui H
    Future Med Chem; 2015 Aug; 7(12):1503-10. PubMed ID: 26334205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system.
    Kibria G; Hatakeyama H; Harashima H
    Arch Pharm Res; 2014 Jan; 37(1):4-15. PubMed ID: 24272889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Progress in the study of drug delivery system based on nanoparticles to overcome multi-drug resistance].
    Chen JN; Shen Q; Li SS
    Yao Xue Xue Bao; 2009 Apr; 44(4):333-7. PubMed ID: 19545047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming multidrug resistance with nanomedicines.
    Ganoth A; Merimi KC; Peer D
    Expert Opin Drug Deliv; 2015 Feb; 12(2):223-38. PubMed ID: 25224685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticle therapeutics: Technologies and methods for overcoming cancer.
    Cerqueira BB; Lasham A; Shelling AN; Al-Kassas R
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):140-51. PubMed ID: 26515260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combating P-glycoprotein-mediated multidrug resistance using therapeutic nanoparticles.
    Zhang Q; Li F
    Curr Pharm Des; 2013; 19(37):6655-66. PubMed ID: 23621532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanocarriers in Improving Chemotherapy of Multidrug Resistant Tumors: Key Developments and Perspectives.
    Chistiakov DA; Myasoedova VA; Orekhov AN; Bobryshev YV
    Curr Pharm Des; 2017; 23(22):3301-3308. PubMed ID: 28403792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy.
    Zhong Y; Meng F; Deng C; Zhong Z
    Biomacromolecules; 2014 Jun; 15(6):1955-69. PubMed ID: 24798476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanodrug delivery systems for targeting the endogenous tumor microenvironment and simultaneously overcoming multidrug resistance properties.
    Li R; Xie Y
    J Control Release; 2017 Apr; 251():49-67. PubMed ID: 28232226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming multiple drug resistance in cancer using polymeric micelles.
    Kesharwani SS; Kaur S; Tummala H; Sangamwar AT
    Expert Opin Drug Deliv; 2018 Nov; 15(11):1127-1142. PubMed ID: 30324813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nano-based strategies to overcome p-glycoprotein-mediated drug resistance.
    Niazi M; Zakeri-Milani P; Najafi Hajivar S; Soleymani Goloujeh M; Ghobakhlou N; Shahbazi Mojarrad J; Valizadeh H
    Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1021-33. PubMed ID: 27267126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor Targeting of Polymeric Nanoparticles Conjugated with Peptides, Saccharides, and Small Molecules for Anticancer Drugs.
    Bayram B; Ozgur A; Tutar L; Tutar Y
    Curr Pharm Des; 2017; 23(35):5349-5357. PubMed ID: 28911307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanocarriers for cancer-targeted drug delivery.
    Kumari P; Ghosh B; Biswas S
    J Drug Target; 2016; 24(3):179-91. PubMed ID: 26061298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin and siRNA Codelivery via Chitosan-Coated pH-Responsive Mixed Micellar Polyplexes for Enhanced Cancer Therapy in Multidrug-Resistant Tumors.
    Butt AM; Amin MC; Katas H; Abdul Murad NA; Jamal R; Kesharwani P
    Mol Pharm; 2016 Dec; 13(12):4179-4190. PubMed ID: 27934479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy.
    Beretta GL; Cavalieri F
    Curr Med Chem; 2016; 23(1):3-22. PubMed ID: 26438248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.